SmithKline shares fall on Avandia blow; EU panel fails to approve antidiabetes drug

Article Abstract:

SmithKline Beecham PLC's shares fell almost 12% after a panel advising the EU's main drug regulator rejected an application for Avandia, the company's antidiabetes medicine. The regulatory action took took precedence over a 14% increase in third-quarter net income and an optimistic prediction by Chief Executive Jan Leschly that the drugmaker is on track to make its full-year goal of 13% per-share earnings growth.

European Union, Securities issued, listed, Antidiabetic Preparations, Hypoglycemic agents, SmithKline Beecham PLC

---

Powderject's shares decline by 16%

Article Abstract:

Powderject Pharmaceuticals PLC saw its share value decline by 16%. The drop in share value, to 830 pence per share, came after the company said that it would postpone the launch of a main product.

Securities prices, Abstract, Powderject Pharmaceuticals PLC

---

Genmab admirers should examine some relationships

Article Abstract:

The article discusses Genmab A.S.' intentions to raise as much as 2.1 billion kroner (Euro281.5 million) through its IPO, which could become the largest-ever biotech IPO in Europe.

Denmark, Organizational history, Pharmaceutical preparations, Genmab A/S

Similar abstracts:

• Abstracts: UPC shares fall on expectations of net regulation. UPC projects net losses will peak in 2000. Russian prosecutors launch new probe into Media Most
• Abstracts: European shares slip, but Ericsson soars 12% on venture with Microsoft. Cisco accelerates European push

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.